These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 28540478)

  • 1. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
    Prieux-Klotz C; Dior M; Damotte D; Dreanic J; Brieau B; Brezault C; Abitbol V; Chaussade S; Coriat R
    Target Oncol; 2017 Jun; 12(3):301-308. PubMed ID: 28540478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors-Induced Colitis.
    Tian Y; Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment.
    Cappelli LC; Naidoo J; Bingham CO; Shah AA
    Immunotherapy; 2017 Jan; 9(1):5-8. PubMed ID: 28000525
    [No Abstract]   [Full Text] [Related]  

  • 4. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: colitis associated with anti-CTLA-4 therapy.
    Gupta A; De Felice KM; Loftus EV; Khanna S
    Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
    Beniwal-Patel P; Matkowskyj K; Caldera F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitor-Induced Colitis.
    Bellaguarda E; Hanauer S
    Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors and gastrointestinal immune-related adverse events.
    Pernot S; Ramtohul T; Taieb J
    Curr Opin Oncol; 2016 Jul; 28(4):264-8. PubMed ID: 27138569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
    Johnston RL; Lutzky J; Chodhry A; Barkin JS
    Dig Dis Sci; 2009 Nov; 54(11):2538-40. PubMed ID: 19104936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
    Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors renal side effects and management.
    Rassy EE; Kourie HR; Rizkallah J; Karak FE; Hanna C; Chelala DN; Ghosn M
    Immunotherapy; 2016 Dec; 8(12):1417-1425. PubMed ID: 28000536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors side effects and management.
    Kourie HR; Klastersky J
    Immunotherapy; 2016 Jun; 8(7):799-807. PubMed ID: 27349979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.
    Abu-Sbeih H; Wang Y
    Inflamm Bowel Dis; 2020 Apr; 26(5):662-668. PubMed ID: 31560045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Eltobgy M; Oweira H; Giryes A; Tekbas A; Decker M
    Immunotherapy; 2017 Nov; 9(14):1175-1183. PubMed ID: 29067884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal Tract Adverse Events.
    Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
    Cramer P; Bresalier RS
    Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
    Mir R; Shaw HM; Nathan PD
    Melanoma Res; 2019 Feb; 29(1):102-106. PubMed ID: 30395075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.